Skip to main content

Table 2 Characteristics of patients who underwent surgical resection (n = 13)

From: Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer

 

No. (%)

Age (years)

 Median

50.5 (IQR 41–57)

Gender

 Male

9 (69.2)

 Female

4 (30.8)

ECOG PS

 One

9 (69.2)

 Two

4 (30.8)

Sidedness of the primary tumor

 Right

3 (23.1)

 Left

10 (76.9)

Number of organs involved

 Median

1

 Range

(1–2)

 One

8 (61.5)

 Greater than one

5 (38.5)

Site of metastasis

 Liver

5 (38.5)

 Lung

1 (7.7)

 LNs

6 (46.2)

 Peritoneum

5 (38.5)

KRAS gene mutation

 Mutant

7 (53.8)

 Wild-type

5 (38.5)

 Unknown

1 (7.7)

Best response to XELOXIRI/A

 CR

1 (7.7)

 PR

10 (76.9)

 SD

2 (15.4)

Surgical resection margin

 

 R0

10 (76.9)

 R1

3 (23.1)

  1. IQR interquartile range; XELOXIRI/A xeloda, oxaliplatin, irinotecan, and avastin; ECOGPS Eastern Cooperative Oncology Group Performance Status; CR complete response; PR partial response; SD stable disease; Primary primary tumor resection